Salmeterol xinafoate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H326763

CAS#: 94749-08-3 (xinafoate)

Description: Salmefamol, also known as AH 3923 or AHR 3929, is a beta2-adrenoceptor agonist. Salmefamol showed a more intense, longer-lasting beta-adrenergic activity than salbutamol did.

Chemical Structure

img
Salmeterol xinafoate
CAS# 94749-08-3 (xinafoate)
Instruction

Theoretical Analysis

Hodoodo Cat#: H326763
Name: Salmeterol xinafoate
CAS#: 94749-08-3 (xinafoate)
Chemical Formula: C30H33NO7
Exact Mass: 331.18
Molecular Weight: 519.594
Elemental Analysis: C, 69.35; H, 6.40; N, 2.70; O, 21.55

Price and Availability

Size Price Availability Quantity
10mg USD 250
25mg USD 450
50mg USD 750
Bulk inquiry

Related CAS #: 18910-65-1 (free base)   94749-08-3 (xinafoate)    

Synonym: AH 3923; AH-3923; AH3923; AHR 3929; AHR-3929; AHR3929; Salmefamol; Salmeterol xinafoate; GR-33343G, Salmetedur, Serevent®

IUPAC/Chemical Name: 1-(4-Hydroxy-3-hydroxymethylphenyl)-2-(4-methoxy-alpha-methylphenethylamino)ethanol 1-hydroxy-2-naphthalenecarboxylic acid

InChi Key: WKLZKCJBRYIIHQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H25NO4.C11H8O3/c1-13(9-14-3-6-17(24-2)7-4-14)20-11-19(23)15-5-8-18(22)16(10-15)12-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-8,10,13,19-23H,9,11-12H2,1-2H3;1-6,12H,(H,13,14)

SMILES Code: CC(NCC(O)C1=CC=C(O)C(CO)=C1)CC2=CC=C(OC)C=C2.O=C(C3=CC=C4C=CC=CC4=C3O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 519.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Carpenter JR. Functional antagonism of isoprenaline, salmefamol, fenoterol and pindolol by carbachol, methacholine and histamine in guinea pig isolated trachealis. Proc West Pharmacol Soc. 1986;29:383-4. PubMed PMID: 2876438.

2: Marmo E, Rossi F, Giordano L, Lampa E, Rsalti F, Di Mezza G. Salmefamol and salbutamol. An experimental comparative study of their action on tracheal and bronchial smooth muscles. Respiration. 1979;38(5):257-65. PubMed PMID: 231807.

3: Canfield SP, Curwain BP, King JA, Price C. Salmefamol: inhibitor or stimulant of gastric acid secretion? [proceedings]. Br J Pharmacol. 1978 Mar;62(3):445P. PubMed PMID: 580408; PubMed Central PMCID: PMC1668132.

4: Gottrup F, Ornsholt J, Daly MJ. The effect of a new beta2-adrenoceptor agonist, salmefamol, on pentagastrin-induced gastric acid secretion in conscious dogs [proceedings]. Br J Pharmacol. 1978 Mar;62(3):444P. PubMed PMID: 580407; PubMed Central PMCID: PMC1668145.

5: Hills EA, Davies S, Geary M. Salmefamol and Salbutamol in exercise-induced asthma in children. Br J Dis Chest. 1976 Apr;70(2):78-82. PubMed PMID: 8070.

6: Sillett RW, Dash CH, McNicol MW. Salmefamol orally in asthmatics - two doses compared. Eur J Clin Pharmacol. 1976 Feb 6;9(4):281-4. PubMed PMID: 786694.

7: Sillett RW, Dash CH, McNicol MW. Comparison of salmefamol with salbutamol aerosols in asthamatics. Eur J Clin Pharmacol. 1976 Feb 6;9(4):277-80. PubMed PMID: 786693.

8: Campbell IA, Dash CH, McHardy GJ, Shotter MV. Comparison of salmefamol and salbutamol in patients with chronic airways obstruction. Br J Clin Pharmacol. 1976 Feb;3(1):151-5. PubMed PMID: 788738; PubMed Central PMCID: PMC1428820.

9: McHardy GJ, Campbell IA, Shotter MV, Dash CH. Proceedings: Comparison of two bronchodilators--salmefamol and salbutamol. Tubercle. 1975 Jun;56(2):171. PubMed PMID: 1103399.

10: Kennedy MC, Posner E, Dash CH. New bronchodilator aerosol, salmefamol, in asthma. Acta Allergol. 1975 Apr;30(1):19-33. PubMed PMID: 1173987.

11: Evans ME, Shenfield GM, Paterson JW. The clinical pharmacology of salmefamol. Br J Clin Pharmacol. 1974 Oct;1(5):391-7. PubMed PMID: 22454916; PubMed Central PMCID: PMC1402468.

12: Lal S, Dash CH, Gribben MD. An economical method of comparing inhaled bronchodilators in reversible diffuse airways obstruction. With special reference to a beta-2 stimulant--salmefamol. Thorax. 1974 May;29(3):317-22. PubMed PMID: 4850526; PubMed Central PMCID: PMC470152.

13: Kennedy MC, Dash CH. The bronchodilator effect of a new adrenergic aerosol--Salmefamol. Acta Allergol. 1972 Feb;27(1):22-6. PubMed PMID: 5067420.